---

Elderly Male with Pacemaker: ADHF + AKI/?Acute-on-CKD + ALI - Evaluation & Management

---

I. INITIAL STABILIZATION & TRIAGE

---

II. ACUTE DECOMPENSATED HEART FAILURE (ADHF) - Evaluation

A. Identify the Precipitant (MANDATORY FIRST STEP)

• Non-adherence to medications or dietary salt restriction
• Medications worsening HF: NSAIDs, thiazolidinediones, TNF inhibitors, cold/flu preparations
• Coronary ischemia - must be systematically investigated in all atherosclerotic patients
• Arrhythmias - atrial/ventricular arrhythmias are common contributors
• Pacemaker issues - pacemaker-mediated cardiomyopathy, lead dislodgement, loss of CRT synchrony, pacemaker syndrome (RV pacing inducing dyssynchrony), or pacemaker dysfunction triggering the decompensation
• Valvular disease - echocardiography is key
• Infection or pulmonary embolism

B. Diagnostic Workup

• Assess pacemaker function: is there appropriate pacing spike + capture?
• Check for loss of pacing, failure to capture, undersensing/oversensing
• Identify underlying rhythm (especially AF - relevant to ALI etiology)
• Signs of new ischemia (may be masked by paced rhythm - use Sgarbossa criteria)

• NT-proBNP/BNP - elevated; confirms HF but also tracks response
• Troponin - elevated in demand ischemia or type 2 MI
• Poor prognostic markers: BUN >43 mg/dL, creatinine >2.75 mg/dL, SBP <115 mmHg (Harrison's 22E)

• CXR: pulmonary congestion (perihilar haziness, Kerley B lines, cardiomegaly, pleural effusion), pacemaker lead positions
• Bedside echo (urgent): EF assessment (HFrEF vs HFpEF), valvular disease, pericardial effusion, wall motion abnormalities, IVC plethora (volume status), lead position
• Echo also assesses for thrombus in left atrium/ventricle (source for limb embolism)

• FBC, electrolytes, creatinine, BUN, eGFR, LFTs, LDH, uric acid
• ABG (if hypoxic), lactate (if suspect low-output/cardiogenic shock or ischemic limb)
• Urine output monitoring, urine Na, urine creatinine, FENa
• D-dimer (if PE suspected)

C. ADHF Phenotyping (determines treatment)

• Hypertensive ADHF - vasodilators first
• Low-output ADHF - cardiorenal syndrome, cool extremities (overlap with ALI!)
• Cardiogenic shock - if BP <90 mmHg, poor perfusion, rising lactate

---

III. CARDIORENAL SYNDROME (CRS) - The Linking Pathophysiology

Pathophysiology (NKF Primer on Kidney Diseases, 8e)

• Elevated right atrial pressure → renal venous hypertension → impaired renal venous outflow
• Increased intraabdominal pressure → renal interstitial pressure → back-pressure on Bowman's capsule → reduced GFR
• This was confirmed in the ESCAPE trial: only right atrial pressure (not cardiac index) correlated with renal dysfunction
• Superimposed neurohormonal activation: RAAS, sympathetic, AVP → sodium and water retention, vasoconstriction
• Pre-existing CKD significantly amplifies vulnerability: rightward and downward shift of the diuretic dose-response curve (Brenner & Rector)

AKI/Acute-on-CKD Evaluation

• Urine microscopy: granular casts → ATN; bland sediment → prerenal
• FENa: <1% prerenal; >2% ATN (caveat: unreliable with diuretics - use FEUrea instead)
• Renal ultrasound: echogenicity (CKD background), obstruction, resistive indices
• Urine protein:creatinine ratio - baseline CKD proteinuria
• Trend creatinine at 6-12 hourly intervals
• Novel biomarkers if available: NGAL, KIM-1, cystatin C

---

IV. ADHF MANAGEMENT - Drug Therapy

1. Diuresis - Primary Therapy

• Furosemide 80 mg oral = Furosemide 40 mg IV = Torsemide 20 mg oral = Bumetanide 1 mg oral/IV

• Administer IV route (oral absorption unreliable in ADHF)
• Double the home oral dose as IV furosemide as a starting point
• In patients with GFR <30 mL/min requiring high doses: bumetanide preferred (minimally impacted by kidney dysfunction, less ototoxicity)
• The DOSE trial: no clear advantage of continuous infusion vs. bolus; no significant difference between low-dose and high-dose strategies in general
• Assess response: urine sodium in first 2 hours >50-70 mEq/L suggests adequate response

1. Add thiazide (metolazone) - "sequential nephron blockade" - monitor K+/Mg2+ closely
2. Mineralocorticoid receptor antagonist (spironolactone) - caution with hyperkalemia, especially with RAAS blockers
3. SGLT2 inhibitor (e.g., empagliflozin) - emerging evidence in acute CRS for proximal nephron blockade - 2025 Systematic Review PMID 40435978
4. Ultrafiltration - controlled fluid removal, electrolyte-neutral, reduces neurohormonal activation

2. Vasodilators

• IV nitroglycerin: first-line in hypertensive ADHF with pulmonary edema; reduces preload and afterload; counteracts sympathetic/RAAS/AVP effects
• IV nitroprusside: more potent; beware cyanide toxicity with prolonged use
• Nesiritide (recombinant BNP): reduces filling pressures; modest diuresis; not shown to improve outcomes vs. standard therapy

3. Inotropes (if low-output state or refractory to diuretics)

• Dobutamine: first-line positive inotrope; reduces SVR; increases CO; beware arrhythmias
• Milrinone: PDE-3 inhibitor; greater reduction in SVR than dobutamine; better if on beta-blockers (acts downstream from beta receptor); requires dose reduction in renal failure (renally excreted, long half-life)
• Dopamine: dose-dependent effects; "renal-dose" dopamine is NOT recommended (ROSE-AHF: no benefit over standard diuretics)
• Levosimendan: calcium sensitizer; not approved in the US; mixed trial results

4. GDMT (Guideline-Directed Medical Therapy) - In-Hospital Continuation

• Beta-blockers: Do NOT abruptly stop in admitted ADHF patients - worsens outcomes; can reduce dose if signs of low output
• ACE inhibitor/ARB/ARNI: Hold or reduce if AKI worsening or hypotension; restart at lowest dose when stable
• MRA (spironolactone/eplerenone): Hold if K+ >5.0 or creatinine rising rapidly
• SGLT2 inhibitors: Growing evidence supports continuation or initiation in stable ADHF with renal dysfunction

---

V. PACEMAKER-SPECIFIC CONSIDERATIONS

1. Check device function immediately: Device interrogation (via programmer) - assess pacing thresholds, sensing, lead impedances, battery status, pacing mode
2. Pacemaker-induced cardiomyopathy: Chronic right ventricular pacing (especially >40% burden) causes dyssynchrony and ventricular dysfunction - may require upgrade to CRT (Cardiac Resynchronization Therapy)
3. Pacemaker syndrome: When ventricle paces before atrium contracts properly → loss of AV synchrony → reduced cardiac output → can precipitate ADHF
4. Rate response settings: Ensure pacemaker rate is appropriate for patient's current metabolic demands
5. Device lead thrombosis: In patients with cardiac implantable electronic devices, consider subclavian/axillary vein thrombosis contributing to ipsilateral limb symptoms
6. Electromagnetic interference: Avoid MRI without pacemaker-safe protocol; defibrillation pads placement considerations

---

VI. ACUTE LIMB ISCHEMIA (ALI) - Evaluation & Management

Clinical Assessment - "The 6 Ps"

Investigations

• Ankle-brachial index (ABI): <0.9 confirms limb ischemia; not always feasible acutely
• Urgent arterial duplex Doppler: Map level of occlusion
• CT angiography (preferred if available): Define level and extent of occlusion, plan intervention - NOTE: contrast load will worsen AKI - weigh risk vs. benefit carefully, consider withholding nephrotoxic drugs, IV hydration
• ECG and echo: Identify cardiac source (AF, LV thrombus)

Management

• UFH IV bolus (5000 units) → continuous infusion targeting aPTT 60-100 sec
• Prevents clot propagation; do not wait for imaging if clinical diagnosis is clear
• UFH preferred over LMWH in AKI (renally cleared LMWH has unpredictable levels)

• Watch for reperfusion injury: compartment syndrome (compartment pressure >30 mmHg → fasciotomy), hyperkalemia, myoglobinuria, metabolic acidosis, renal failure worsening
• Myoglobinuria: aggressive IV fluids, urinary alkalinization; this will directly worsen AKI
• Repeat neurological/vascular exam hourly post-intervention

• If AF confirmed: long-term anticoagulation (DOACs preferred, but dose-adjust for CKD)
• If LV thrombus: warfarin (target INR 2-3) for 3-6 months

---

VII. INTEGRATED MANAGEMENT CHALLENGES

---

VIII. INDICATIONS FOR RENAL REPLACEMENT THERAPY (RRT)

• Refractory volume overload despite diuretics/UF
• Severe hyperkalemia (K+ >6.5 mEq/L or ECG changes) unresponsive to medical therapy
• Severe metabolic acidosis (pH <7.15)
• Uremic symptoms (encephalopathy, pericarditis)
• Inability to clear fluid to achieve adequate decongestion

---

IX. MONITORING TARGETS

---

X. DISPOSITION

• ICU/HDU admission given triple-organ threat (cardiac, renal, vascular)
• Multidisciplinary team: Cardiology, Nephrology, Vascular Surgery, Device/EP Clinic
• Vascular surgery: STAT consultation for ALI
• Device clinic/EP: Pacemaker interrogation
• Avoid iodinated contrast until vascular access secured and renal risk assessed
• Avoid NSAIDs, nephrotoxic antibiotics, gadolinium contrast

---

Recent Evidence Updates

• Systematic Review on Diuretic Resistance in Acute HF (2025, PMID 40435978) - SGLT2 inhibitors show promise as adjuncts for natriuresis in CRS with diuretic resistance
• Comparative efficacy of drugs in AHF with renal dysfunction (2024, PMID 39877019) - Network meta-analysis comparing agents; tolvaptan and combination diuretics show benefit
• AKI incidence and predictors in heart failure (2023, PMID 37705352) - AKI in HF carries significantly elevated mortality; creatinine rise >0.3 mg/dL is an independent predictor of poor outcomes

---

---

Elderly Male with Pacemaker: ADHF + AKI/?Acute-on-CKD + Acute Liver Injury - Evaluation & Management

---

THE UNIFYING CONCEPT: Congestive Multi-Organ Failure

• Renal venous hypertension → AKI/Acute-on-CKD (Cardiorenal Syndrome Type 1)
• Hepatic venous congestion → Congestive hepatopathy ± Ischemic hepatitis ("shock liver")

---

I. IMMEDIATE STABILIZATION

---

II. ACUTE DECOMPENSATED HEART FAILURE (ADHF)

A. Identify the Precipitant (Do This Before Any Drug)

• Device interrogation is mandatory - check sensing, pacing thresholds, lead impedances, battery status, % RV pacing
• Chronic RV pacing (>40% burden) → pacemaker-induced cardiomyopathy (dyssynchrony) → may need CRT upgrade
• Pacemaker syndrome: retrograde VA conduction → loss of AV synchrony → reduced CO
• Rule out pacemaker lead dislodgement or failure to capture

B. ADHF Phenotyping

• Known heart block + pacemaker (structural/electrical cardiac disease)
• Signs of multi-organ venous congestion (kidney + liver)
• Note: hepatic congestion is explicitly listed as a feature of the "Low Output" ADHF phenotype in the flowchart above

C. Investigations for ADHF

• Pacemaker spikes present? Capture? Rate?
• Underlying rhythm (AF, ventricular ectopy)
• Sgarbossa criteria for ischemia in paced rhythm
• PR, QRS, QTc

• NT-proBNP/BNP: confirms HF, tracks response; >1000 pg/mL with HFrEF is typical
• High-sensitivity troponin (T or I): type 2 MI (demand ischemia from low output)
• Poor prognostic markers (Harrison's): BUN >43 mg/dL, SBP <115 mmHg, creatinine >2.75 mg/dL, elevated troponin

• CXR: pulmonary congestion, cardiomegaly, pleural effusions, pacemaker lead position
• Bedside echo (urgent): EF (HFrEF vs HFpEF), RWMA (ischemia), valvular disease, pericardial effusion, IVC diameter/collapsibility (volume status), RV function, pacemaker lead position
• Dilated IVC + hepatic veins on echo directly confirms hepatic venous congestion

---

III. CARDIORENAL SYNDROME - AKI / Acute-on-CKD

Pathophysiology

• Central venous pressure → renal venous hypertension → reduced net renal perfusion pressure
• Intraabdominal pressure → transmitted to renal interstitium → back-pressure on Bowman's capsule → reduced GFR
• Neurohormonal activation (RAAS, SNS, AVP) → Na/water retention → worsens volume overload

AKI Evaluation

• Baseline creatinine from old records?
• AKI Stage 1: Cr rise ≥0.3 mg/dL within 48h or ≥1.5x baseline within 7 days
• AKI Stage 2: Cr ≥2x baseline
• AKI Stage 3: Cr ≥3x baseline or <0.3 mL/kg/hr x 24h

---

IV. ACUTE LIVER INJURY IN HEART FAILURE

A. Congestive Hepatopathy ("Cardiac Liver")

• Dull right upper quadrant ache
• Hepatomegaly (often tender)
• Hepatojugular reflux (compression over liver raises JVP)
• Pulsatile liver if tricuspid regurgitation is present
• Ascites (may need paracentesis if tense)
• Mild elevation of bilirubin (<3 mg/dL in most; jaundice in <10%)
• Prothrombin time prolonged in >75% - resistant to Vitamin K (hepatic dysfunction, not just coagulation factor deficiency)
• Spider angiomata and varices are usually absent
• Liver tests improve slowly with effective HF treatment

• LFTs: bilirubin (mild), ALP, GGT (elevated), ALT/AST (mild-moderate)
• INR/PT: prolonged
• Serum albumin: reduced in advanced disease
• USS/CT: hepatomegaly, dilated IVC + hepatic veins, ascites, portal hypertension signs
• CT portal phase: inhomogeneous hepatic enhancement ("nutmeg" pattern)

B. Ischemic Hepatitis ("Shock Liver")

• Low cardiac output (cardiogenic shock, severe HF)
• Arrhythmias (sustained VT/VF, complete AV block breakthrough)
• Myocardial infarction
• Cardiogenic shock

• Systemic hypotension + marked rapid elevation of serum aminotransferases (typically >1000 IU/mL) - rapidly reversible with treatment
• LDH markedly elevated with a low AST:LDH ratio - helps distinguish from viral hepatitis (in viral hepatitis, AST:LDH ratio is higher)
• Concomitant AKI almost always present (renal hypoperfusion)
• Classic histology: centrilobular necrosis
• Exclude other causes: viral hepatitis (HAV, HBV, HCV serology), drug/toxin-induced, autoimmune

---

V. INTEGRATED MANAGEMENT STRATEGY

1. Diuresis - Cornerstone of Therapy

Furosemide 80 mg oral = Furosemide 40 mg IV = Torsemide 20 mg oral = Bumetanide 1 mg oral/IV

• IV route mandatory (oral absorption unreliable - furosemide bioavailability 10-90%, mean 50%)
• Start at double the home oral dose as IV furosemide
• Monitor urine output and urine Na+ at 1-2 hours post-dose; spot urine Na+ >50-70 mEq/L = adequate response
• DOSE trial: No significant difference between continuous infusion and bolus dosing; no need to routinely use infusion over bolus
• In CKD with GFR <30: bumetanide preferred - minimally affected by renal dysfunction, less ototoxicity

1. Add metolazone (thiazide) for sequential/dual nephron blockade - monitor K+/Mg2+ closely
2. Add spironolactone/eplerenone (MRA) - only if K+ <5.0 and creatinine stable
3. SGLT2 inhibitor (e.g., empagliflozin) - proximal nephron blockade; emerging evidence in acute CRS (Systematic Review 2025, PMID 40435978)
4. Ultrafiltration - precise, electrolyte-neutral fluid removal; preferred when diuretics fail

• Normalize JVP
• Clear pulmonary rales
• Resolve peripheral edema and hepatomegaly
• Reduce ascites
• Suppress BNP/NT-proBNP toward discharge
• Improve liver tests (will improve as congestion resolves)

2. Vasodilators

• IV nitroglycerin: first-line in hypertensive ADHF (SBP >140) + pulmonary edema
• Reduces preload and afterload; counteracts sympathetic/RAAS/AVP-mediated vasoconstriction
• IV nitroprusside: more potent; use with BP monitoring; caution in renal failure (thiocyanate toxicity)
• Avoid vasodilators if SBP <90 mmHg (worsens hepatic and renal perfusion)

3. Inotropes (Low-Output State / Cardiogenic Shock)

4. Mechanical Circulatory Support (if refractory)

• Ultrafiltration / CRRT: preferred over intermittent HD in hemodynamically unstable patients (avoids BP swings that worsen hepatic and renal ischemia)
• IABP, Impella, VA-ECMO: for cardiogenic shock refractory to medical management

5. GDMT Continuation

---

VI. SPECIFIC HEPATIC MANAGEMENT

• Aminotransferases typically normalize within 1-2 weeks if systemic perfusion is restored
• Do NOT perform liver biopsy acutely - diagnosis is clinical
• Exclude viral hepatitis and drug causes with serology + drug history
• Acute liver failure workup (INR, ammonia, encephalopathy assessment) if rapidly deteriorating

---

VII. DRUG PRESCRIBING IN TRIPLE ORGAN DYSFUNCTION

---

VIII. MONITORING TARGETS

---

IX. INDICATIONS FOR RENAL REPLACEMENT THERAPY

• Refractory volume overload
• K+ >6.5 mEq/L or ECG changes unresponsive to medical therapy
• Metabolic acidosis (pH <7.15)
• Uremic encephalopathy or pericarditis
• Inability to achieve adequate decongestion with diuretics/UF

---

X. INDICATIONS FOR LIVER FAILURE WORKUP / HEPATOLOGY REFERRAL

• INR >1.5 with encephalopathy (acute liver failure criteria - King's College criteria)
• Bilirubin rapidly rising
• Hepatic encephalopathy (confusion, asterixis, elevated ammonia)
• Does not improve with cardiac treatment (suggests alternative diagnosis)

• N-acetylcysteine (improves microcirculatory flow; some evidence in non-paracetamol ALF)
• Lactulose + rifaximin for encephalopathy
• Vitamin K 10 mg IV x3 days (though likely resistant)
• Fresh frozen plasma only if bleeding (not for INR correction alone - distorts prognostication)
• CRRT + plasma exchange in severe cases

---

XI. DISPOSITION & TEAM

---

XII. KEY CLINICAL PITFALLS TO AVOID

1. Withholding diuresis for fear of worsening AKI - venous congestion is the primary driver of AKI; aggressive decongestion improves survival even if creatinine rises transiently (Brenner & Rector)
2. Attributing all liver injury to intrinsic hepatic disease - 95% of liver injury in ADHF is congestive/ischemic and will recover with cardiac treatment
3. Using "renal-dose" dopamine - no benefit (ROSE-AHF)
4. Giving vitamin K for coagulopathy without liver disease context - resistance to vitamin K confirms hepatic synthetic failure
5. Not interrogating the pacemaker - device dysfunction may be the primary precipitant
6. Stopping beta-blockers abruptly - worsens outcome in ADHF; reduce dose if needed
7. NSAIDs for any pain - contraindicated in this triple-organ dysfunction setting
8. Failing to check ammonia if patient is confused - hepatic encephalopathy can masquerade as "delirium" in elderly patients

---

Recent Evidence

• Congestive Hepatopathy Review (2024, PMID 38779242) - comprehensive review confirming treatment of underlying cardiac disease is the cornerstone; liver tests normalize with effective HF management
• Diuretic Resistance in Acute HF with Kidney Disease (2025, PMID 40435978) - SGLT2 inhibitors as adjuncts show promise; urine Na monitoring superior to weight for early diuretic response assessment
• ADHF Management Review (2025, PMID 41133931) - personalized approach to congestion; acetazolamide (ADVOR trial) aids decongestion but does not reduce readmissions

---